SEHK:867Pharmaceuticals
China Medical System Expands AI Drug Pipeline As Valuation Gap Persists
China Medical System Holdings (SEHK:867) has partnered with Insilico Medicine to co-develop AI supported drug discovery programs in central nervous system and autoimmune diseases.
The company also received clinical trial approval for its selective complement factor B inhibitor CMS-D017 in kidney disease and paroxysmal nocturnal hemoglobinuria.
China Medical System Holdings, trading at HK$15.13, has seen its share price gain 7.8% over the past month and 15.4% year to date, with a 1 year...